checkAd

     947  0 Kommentare Positive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degeneration - Seite 3

    About Novartis
    Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.

    Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Novartis AG!
    Short
    99,83€
    Basispreis
    0,73
    Ask
    × 13,36
    Hebel
    Long
    86,94€
    Basispreis
    0,77
    Ask
    × 12,66
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    *Aflibercept is marketed under the brand name of Eylea® in the United States by Regeneron and outside the United States by Bayer, and is a prescription medicine for the treatment of patients with wet AMD, macular edema following retinal vein occlusion (RVO), and diabetic macular edema (DME).

    References
    [1] National Eye Institute. Facts About Age-Related Macular Degeneration. http://www.nei.nih.gov/health/maculardegen/armd_facts.asp.
    [2] Klein R, et al "Incidence of visual impairment over a 20-year period" Ophthalmology 2013; DOI: 10.1016/j.ophtha.2013.11.041. http://bmctoday.net/practicaldermatology/dermwire/view.asp?20130405-am ....
    [3] BMJ, 2003 March 1; 326(7387): 485-488. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1125371/

    # # #

    Novartis Media Relations

    Central media line : +41 61 324 2200  
    Eric Althoff
    Novartis Global Media Relations
    +41 61 324 7999 (direct)
    +41 79 593 4202 (mobile)
    eric.althoff@novartis.com
    Elizabeth Harness Murphy
    Alcon Global Communications
    +1 817 551 8696
    +1 585 435 7379
    elizabeth.murphy@alcon.com

    e-mail: media.relations@novartis.com

    Lesen Sie auch

    For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
    For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.

    Seite 3 von 4


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Positive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degeneration - Seite 3 Novartis International AG / Positive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degeneration . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely …

    Schreibe Deinen Kommentar

    Disclaimer